RSS

metastatic breast cancer

A research team from immuno-oncology focused biotechnology company, BriaCell Therapeutics, has published a paper shedding light on the potentially unique mechanism of action of the company’s lead product candidate, Bria-IMT, at shrinking tumours. more

News

The US Food and Drug Administration (FDA) has accepted and granted priority review of a supplemental new drug application (sNDA) for Lynparza to be used in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer. more

News